Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01688921 · ClinicalTrials.gov registry record · Phase 4

Jet Injection for Influenza

A Phase 4 study, sponsored by PharmaJet.

Completed
Registry status
Phase 4
Development phase
1,250
Enrollment target

NCT01688921: Completed Phase 4 study, sponsored by PharmaJet.

NCT01688921 is a Phase 4 study that has completed, run by PharmaJet. The registered enrollment target is 1,250 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (141% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01688921, a Phase 4 study, has completed, sponsored by PharmaJet.

COMPLETED
Registry status
Phase 4
Development phase
1,250 participants
Enrollment target

Study Summary

The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory tests of immune response.

Primary Outcome

The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.

Interventions

  • BIOLOGICAL AFLURIA vaccine (2012-2013 formulation)
  • DEVICE Needle-Syringe
  • DEVICE Stratis needle-free injection device

Trial Details

FieldValue
Enrollment Target 1,250 participants
Start Date 2012-10
Est. Completion 2013-03
Phase Phase 4
PharmaJet

5 total trials

What the finished NCT01688921 record still lists

NCT01688921 is an interventional study that assigns participants to a tested intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (141% higher).

The record links to 0 conditions, and to 3 interventions - of which AFLURIA vaccine (2012-2013 formulation) is the first listed.

NCT01688921 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01688921 about?

NCT01688921 is a clinical study titled "Jet Injection for Influenza". The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory tests of immune response.

What is the current status of trial NCT01688921?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,250 participants. The study started on 2012-10. Estimated completion is 2013-03.

What interventions are being tested in trial NCT01688921?

The interventions under investigation include: AFLURIA vaccine (2012-2013 formulation) (BIOLOGICAL), Needle-Syringe (DEVICE), Stratis needle-free injection device (DEVICE).

Who is sponsoring clinical trial NCT01688921?

This trial is sponsored by PharmaJet, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01688921's enrollment target sits among peer trials

1,250 62nd of 2000 higher than 1,939 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02743858 · 1,250 participants

    Lymphedema Surveillance Study

  • NCT04670874 · 1,250 participants

    Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

  • NCT04807868 · 1,250 participants

    AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

  • NCT05995821 · 1,250 participants

    Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01688921, the US trial registry maintained by the National Library of Medicine. NCT01688921 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.